John Sfakianos, MD
Invited Faculty
John Sfakianos, MD
Assistant Professor of Urology
Icahn School of Medicine at Mount Sinai
New York, New York

Expertise: Adrenocortical Carcinoma, Benign Prostatic Hyperplasia, Bladder Cancer, Cystectomy, Cystoscopy, Elevated PSA, Evaluation of Kidney Mass, Hematuria, Hydronephrosis, Kidney Cancer, Laparoscopy, Vasectomy Nephrectomy, Penile Cancer, Prostate Biopsy, Prostate Cancer, Prostate Laser Procedures

  • Friday, February 19th 11:50–1:00 pm

    Bladder Session I – Single Port Female Cystectomy


    Cystectomy is the standard treatment for bladder recurrent, high‐risk non‐muscle‐invasive and localized muscle‐invasive urothelial carcinoma of the bladder. The da Vinci single-port instrument configuration allows the surgeon to work in narrow spaces. The instruments also have an extra joint providing an ‘elbow’, enhancing the triangulation experience around the target anatomy. The system features: a high‐definition three‐dimensional camera, an instrument guidance system, and enhanced instrument arm control.

  • Friday, February 19th 4:20–5:30 pm

    Bladder Session II – Male Nerve Sparing Cystectomy with NeoBladder


    Male Nerve Sparing Cystectomy with NeoBladder can improve early to urinary continence and erectile function.

  • Saturday, February 20th 11:50 am–1:00 pm

    Bladder Session III – Male Cystectomy: Ileal Conduit


    Robot-assisted radical cystectomy (RARC) is an increasingly common treatment approach for bladder cancer. RARC replicates the oncologic outcomes of open surgery while providing benefits of a minimally invasive approach. Additionally, an ileal conduit is feasible and can shorten operative time as compared to neobladder methods.

  • Saturday, February 20th 3:00–4:10 pm

    Kidney Session IV – RPLND


    RPLND can affect oncologic outcomes. It is possible that robotic approaches make these steps of the procedure technically easier and better patient experience.